Press Releases

    • April 21, 2020

    Nemaura Secures $5 Million Loan to Accelerate Commercial Strategy

    Loughborough, England, April 21, 2020 — Nemaura Medical Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company...

    Read more
    April 1, 2020

    Nemaura Plans To Launch Body-Worn Continuous Temperature Monitor (CTM) to Track Fever Caused by Viral Infections such as COVID-19

    BEAT® platform is planned to be extended to conditions requiring continuous temperature monitoring including viral infections and poor blood...

    Read more
    March 30, 2020

    Nemaura to launch new digital brand proBEAT™ in the USA, Targeting a Market of over 100 Million potential users with its Prescription-Free Consumer Wellness Glucose Monitoring Device and Digital Healthcare Subscription Service

      Loughborough, England, March 30, 2020 — Nemaura Medical Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology...

    Read more
    March 10, 2020

    Nemaura Medical enters into multiple verbal non-binding agreements for its sugarBEAT® platform

    sugarBEAT® strategic global partnership(s) a step closer as Nemaura Medical enters into multiple verbal non-binding agreements Loughborough, England, March...

    Read more
    March 3, 2020

    Nemaura Medical Launches sugarBEAT® App on Play Store Ahead of its Planned Commercial Launch of BEAT®diabetes Subscription Service

    sugarBEAT® App is now available on Play Store with iOS app planned to follow, ahead of the planned BEAT®diabetes...

    Read more
    February 25, 2020

    Nemaura Medical Plans Head-to-Head Study with Major Glucose Monitoring System

    Studies planned to compare sugarBEAT® and major continuous glucose monitor sensor, seeking to position sugarBEAT® as both a possible...

    Read more
    February 11, 2020

    Nemaura Medical Reports Results and Provides Business Update for the Third Quarter Ended December 31, 2019

    Loughborough, England, Feb. 11, 2020 (GLOBE NEWSWIRE) — – Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura”), a medical technology company...

    Read more
    December 20, 2019

    Nemaura Provides 2019 Year-End Corporate Update

    Loughborough, England, Dec. 20, 2019 (GLOBE NEWSWIRE) —  Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company commercializing sugarBEAT®,...

    Read more
    December 5, 2019

    Nemaura Medical announces expansion of SugarBEAT® offering with BEAT® Diabetes digital subscription services

    BEAT® Diabetes utilizes SugarBEAT® CGM data to provide holistic coaching services via user-friendly app to enhance outcomes for diabetic...

    Read more
    December 4, 2019

    Nemaura Medical Announces 1 for 10 Reverse Split Intended to Attract a Wider Universe of Institutional Investors

    Loughborough, England, Dec. 04, 2019 (GLOBE NEWSWIRE) —  Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura”), a medical technology company focused...

    Read more